Condition: Chronic Hepatitis D Infection · Sponsor: Mirum Pharmaceuticals, Inc.
This is a Phase 3, global, randomized, open-label, multicenter, trial evaluating brelovitug (BJT-778) vs bulevirtide for the treatment of chronic hepatitis delta infection (CHD). The main goal of this study is to test the effectiveness of brelovitug compared to bulevirtide as a long-term treatment in patients with chronic HDV infection.
This description comes directly from the study's public registry record.
Clinical Trials Clinical Trials Mirum · +16506674085 · clinicaltrials@mirumpharma.com
Mirum Pharmaceuticals, Inc., Clinical Trials
Always discuss trial participation with your own doctor first.
| Medical University of Graz | Graz, Austria | Recruiting |
| Universitätsklinikum St. Pölten | Sankt Pölten, Austria | Recruiting |
| Fakultni Nemocnice Brno | Brno, Brno, Czechia | Recruiting |
| Fakultni Nemocnice Hradec Kralove | Hradec Králové, Hradec Králové, Czechia | Recruiting |
| Krajská nemocnice Liberec, a.s. | Liberec, Liberec, Czechia | Recruiting |
| Institute For Clinical And Experimental Medicine | Prague, Prague, Czechia | Recruiting |
| Klin Med s.r.o. | Prague, Prague, Czechia | Recruiting |
| Hôpital Estaing | Clermont-Ferrand, France | Recruiting |
| Hôpital Beaujon | Clichy, France | Recruiting |
| University Hospital Henri Mondor - APHP | Créteil, France | Recruiting |
| CHU Grenoble Alpes Hopital Nord Michallon | La Tronche, France | Recruiting |
| Centre Hospitalier de Versailles _ Hopital Andre Magnot | Le Chesnay, France | Recruiting |
+ 36 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07200908